Keisuke Kakisaka, Takuya Watanabe, Yuichi Yoshida, Hiroaki Abe, Kenji Yusa, Tokio Sasaki, Yudai Fujiwara, Tamami Abe, Akiko Suzuki, Kei Endo, et al. Body mass index of 23 or greater is relevant to hepatic steatosis and fibrosis in patients with harmful alcohol use. Hepatology research : the official journal of the Japan Society of Hepatology. 2024
Yudai Fujiwara, Hidekatsu Kuroda, Tamami Abe, Keisuke Kakisaka, Ippeki Nakaya, Asami Ito, Takuya Watanabe, Kenji Yusa, Tomoaki Nagasawa, Hiroki Sato, et al. Early Clinical Outcomes of Durvalumab Plus Tremelimumab in Unresectable Hepatocellular Carcinoma: A Real-World Comparison with First-Line or Later-Line Treatment. Drugs - real world outcomes. 2024
Kei Endo, Keisuke Kakisaka, Tamami Abe, Kenji Yusa, Ippeki Nakaya, Takuya Watanabe, Hiroaki Abe, Akiko Suzuki, Yuichi Yoshida, Takayoshi Oikawa, et al. Grip strength complements performance status in assessing general condition in patients with unresectable hepatocellular carcinoma treated with atezolizumab and bevacizumab. Hepatology research : the official journal of the Japan Society of Hepatology. 2024
Keisuke Kakisaka, Tokio Sasaki, Ippeki Nakaya, Takuya Watanabe, Hiroaki Abe, Kenji Yusa, Yudai Fujiwara, Tamami Abe, Akiko Suzuki, Kei Endo, et al. Low liver reserve is a risk factor for acute pancreatitis in patients with acute liver failure. Hepatology research : the official journal of the Japan Society of Hepatology. 2024
吉田 雄一, 宮坂 昭生, 滝川 康裕. 日本の肝がん死の減少を目指して-受検・受診・受療・フォローのCascade of care(疫学・政策) 透析患者におけるmicro-elimination of HCVの現状と課題. 肝臓. 2022. 63. Suppl.1. A182-A182
宮坂 昭生, 吉田 雄一, 鈴木 彰子, 滝川 康裕. 実臨床におけるGenotype 1型C型肝炎に対するエルバスビル・グラゾプレビルの治療効果と安全性(The efficacy and safety of elbasvir and grazoprevir for hepatitis C virus genotype 1 in a real clinical setting). 岩手医学雑誌. 2022. 74. 1. 11-19